Comparison of Costs and Healthcare Resource Utilization in Patients with CLL Treated with Frontline Ibrutinib or Chemoimmunotherapy
When used in first-cycle therapy for chronic lymphocytic leukemia (CLL), rates of resource utilization and total costs of care were significantly lower for ibrutinib than for chemotherapy or chemoimmunotherapy, with ibrutinib-treated patients having lower emergency department and inpatient costs per month and less frequent office and outpatient visits than patients treated with chemotherapy or chemoimmunotherapy.
Preliminary Results of Prophylactic Tocilizumab After Axicabtagene Ciloleucel (axi-cel; KTE-C19) Treatment for Patients with Relapsed/Refractory, Aggressive NHL
In patients with relapsed/refractory, aggressive non-Hodgkin lymphoma (NHL), use of prophylactic tocilizumab may reduce the incidence of severe cytokine release syndrome but not neurologic events in patients treated with chimeric antigen receptor T-cell therapy.
Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA
The findings of the current study suggest that patients with rheumatoid arthritis (RA) who achieve low disease activity with subcutaneous tocilizumab plus methotrexate (MTX) may potentially discontinue MTX and maintain disease control with tocilizumab monotherapy.
Longer Duration of Response in MOBILITY Study with Sarilumab plus MTX in Patients with Active, Moderate-to-Severe RA
This analysis showed that patients with active, moderate-to-severe rheumatoid arthritis (RA) treated with sarilumab plus methotrexate (MTX) achieved longer duration of response versus those treated with placebo plus MTX, regardless of the definition of response used.
Improvements in Remission and Low Disease Activity Achieved with Ongoing Sarilumab Treatment in Patients with RA
This post-hoc analysis showed that ongoing sarilumab treatment on the MOBILITY and TARGET studies resulted in achievement of remission or low disease activity increased through week 24 in patients with rheumatoid arthritis (RA) and inadequate response to methotrexate and inadequate response to, or intolerance of, tumor necrosis factor inhibitors.
Efficacy and Safety of Switching from Adalimumab to Sarilumab in Open-Label Extension of MONARCH Trial in Patients with Active RA
In the open-label extension phase of the phase 3 MONARCH trial, patients switching from monotherapy with adalimumab 40 mg to open-label monotherapy with sarilumab 200 mg every 2 weeks demonstrated improvements in rheumatoid arthritis (RA) signs and symptoms and physical function that were numerically similar to patients who were initially randomized to sarilumab 200 mg every 2 weeks.
Improvements in PROs with Tofacitinib with and without MTX versus Adalimumab with MTX for the Treatment of RA
The findings of this study showed that patients with rheumatoid arthritis (RA) who had an inadequate response to methotrexate (MTX) reported clinically meaningful improvements in patient-reported outcomes (PROs) with all 3 treatment regimens (tofacitinib monotherapy, tofacitinib plus MTX, and adalimumab plus MTX). PROs were comparable between tofacitinib plus MTX and adalimumab plus MTX therapies, with combination therapy numerically higher than tofacitinib monotherapy.
Post-hoc pooled analyses of the MOBILITY and TARGET trials showed that sarilumab plus disease-modifying antirheumatic drug (DMARD) treatment in diabetic patients with rheumatoid arthritis (RA) led to reductions in glycosylated hemoglobin (HbA1c) and lowered fasting glucose levels; reductions in HbA1c were also achieved by nondiabetic patients with RA.
Highly Sensitive Cardiac Troponin I Levels in Peripheral Blood Predict CV Events in Patients with RA
Page 7 of 19
Results 61 - 70 of 190
Results 61 - 70 of 190